NYLIM
PASG icon

New York Life Investment Management’s Passage Bio PASG Stock Holding History

New York Life Investment Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,149
Closed -$253K – 1338
2022
Q4 		$253K Buy
9,149
+1,031
+13% +$26K ﹤0.01% 1148
2022
Q3 		$203K Buy
8,118
+596
+8% +$23.5K ﹤0.01% 1182
2022
Q2 		$355K Buy
+7,522
New +$351K ﹤0.01% 1079

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

New York Life Investment Management's PASG Position: Q1 2023 in Review

New York Life Investment Management sold out of Passage Bio (PASG) in Q1 2023, closing a stake of 9,149 shares — an estimated $253K sold.

New York Life Investment Management first reported a position in PASG in Q2 2022 and held it in 3 quarters. The position peaked at $355K in Q2 2022. 58 funds tracked by Wall St. Rank hold PASG as of Q1 2023.

  • New York Life Investment Management reported no remaining Passage Bio position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 9,149 Passage Bio shares in Q1 2023, an estimated $253K.
  • New York Life Investment Management first reported a position in Passage Bio in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Passage Bio position peaked at $355K in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Passage Bio as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.